IL-3-LA PRODUCTION BY MONONUCLEAR-CELLS OF PATIENTS WITH MULTIPLE-SCLEROSIS - EFFECT OF TREATMENT WITH INTRAVENOUS IMMUNOGLOBULINS

被引:3
作者
DJALDETTI, R
ACHIRON, A
ZIV, I
DJALDETTI, M
MELAMED, E
FISHMAN, P
机构
[1] BEILINSON MED CTR,FELSENSTEIN RES CTR,IL-49100 PETAH TIQWA,ISRAEL
[2] GOLDA MEIR MED CTR,IMMUNOL RES INST,PETAH TIQWA,ISRAEL
关键词
IL-5-LIKE ACTIVITY; MULTIPLE SCLEROSIS; INTRAVENOUS IMMUNOGLOBULINS;
D O I
10.3109/08820139509060704
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-3-like activity (IL-3-LA) is a growth factor that stimulates stem cell maturation. We examined the production of IL-3-LA by peripheral blood mononuclear cells of 10 patients with relapsing-remitting multiple sclerosis (MS) following one year of treatment with intravenous immunoglobulins (IVIG). The results were compared with those obtained in 13 age- and sex-matched untreated patients with relapsing-remitting MS and in 14 healthy controls. IL-3-LA was assayed using the IL-3-dependent 32-D-cl-23 murine cell line. IL-3-LA production was 60% higher in untreated MS patients than in healthy controls (134+/-19 u/ml and 78.7+/-15.9 u/ml, respectively; p<0.01), and lower in patients treated with IVIG than in untreated patients (101.4+/-4.9 u/ml; p<0.02). IL-S-LA production also decreased after incubation of mononuclear cells with IVIG of both untreated MS patients and controls. This study indicates a possible beneficial effect of IVIG on the immunological status of MS patients.
引用
收藏
页码:765 / 773
页数:9
相关论文
共 23 条
[1]   OPEN CONTROLLED THERAPEUTIC TRIAL OF INTRAVENOUS IMMUNE GLOBULIN IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS [J].
ACHIRON, A ;
PRAS, E ;
GILAD, R ;
ZIV, I ;
MANDEL, M ;
GORDON, CR ;
NOY, S ;
SAROVAPINHAS, I ;
MELAMED, E .
ARCHIVES OF NEUROLOGY, 1992, 49 (12) :1233-1236
[2]  
ALCOCER-VARELA A V, 1988, Clinical and Experimental Immunology, V73, P424
[3]   EXPERIENCE WITH INTRAVENOUS IMMUNOGLOBULIN IN MYASTHENIA-GRAVIS [J].
ARSURA, E .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1989, 53 (02) :S170-S179
[4]  
BACH MA, 1985, J NEUROIMMUNOL, V7, P331
[5]   SERUM SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN CHRONIC PROGRESSIVE, STABLE AND STEROID-TREATED MULTIPLE-SCLEROSIS [J].
BANSIL, S ;
TROIANO, R ;
COOK, SD ;
ROHOWSKYKOCHAN, C .
ACTA NEUROLOGICA SCANDINAVICA, 1991, 84 (04) :282-285
[6]  
CALDER VL, 1987, CLIN EXP IMMUNOL, V70, P570
[7]   TREATMENT OF REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA WITH AN ANTI-FC-GAMMA-RECEPTOR ANTIBODY [J].
CLARKSON, SB ;
BUSSEL, JB ;
KIMBERLY, RP ;
VALINSKY, JE ;
NACHMAN, RL ;
UNKELESS, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (19) :1236-1239
[8]  
DWYER JM, 1992, NEW ENGL J MED, V326, P107
[9]  
FETAHMOGHADAM A, 1984, LANCET, V1, P848
[10]  
FISHMAN P, 1990, NAT IMMUN CELL GROW, V9, P334